Correlation Study Of DNA Repair Gene XRCC1Single Nucleotide Polymorphism With Sensitivity Of Platinum Chemotherapy In Nasopharyngeal Carcinoma

Objective:To explore correlation of codon194and codon399singlenucleotide polymorphisms (SNP) of DNA repair gene X-ray repaircross-complementing gene1（XRCC1）with the sensitivity of nasopharyngealcarcinoma （NPC）to platinum chemotherapy.Methods: The biopsy specimens obtained through nasopharyngealendoscopy from patients of NPC in the Fourth Affiliated Hospital of GuangxiMedical University from September1,2012to December31,2013. XRCC1SNPat codon194and codon399in patients with NPC were detected usingpolymerase chain reaction-restriction fragment length polymorphism(PCR-RFLP).21days after the end of2periods of PF (cisplatin+5-fluorouracil) induction chemotherapy, MRI is taken,according to RECIST1.1standard through the imaging results to assess the efficacy.CR+PR was sensitive group,SD+PD was insensitive group,assess the relationship betweenSNP and the sensitivity of chemotherapy in patients with nasopharyngealcancer.Results:158cases were collected.153cases were evaluable for thesensitivity of chemotherapy.153curative effect evaluable cases, respectively,CR2cases (1.31%), PR76cases(49.67%), SD74cases(48.37%), PD1cases(0.65%).The genotyping of153cases were clear. The number ofArg/Arg,Arg/Trp and Trp/Trp genotypes at XRCC1codon194were84(54.9%),57(37.3%) and12(7.8%), respectively. The number of Arg/Arg,Arg/Gln andGln/Gln genotypes at XRCC1codon399were75(49.0%),63(41.2%) and15(9.8%),respectively. The genotype distribution conformed with Hardy-Weinbergequilibrium of population genetics,(P>0.1). The patients with the XRCC1codon399Gln/Gln polymorphisms were3.500times as sensitive to thechemotherapy as the patients with Arg/Arg genotype (95CI%=1.021-11.997),the patients with the XRCC1codon399Gln/Gln polymorphisms were3.274times as sensitive to the chemotherapy as the patients with (Arg/Arg+Arg/Gln)genotype (95CI%=0.994-10.787).The sensitivity to chemotherapywas no significant difference between the patients with XRCC1codon194Arg/Arg,Arg/Trp,Trp/Trp polymorphism (P>0.05).Conclusion:The XRCC1codon399SNP might be a useful predictive marker in NPC patients treated with cisplatin-based chemotherapy. However, alarge-scale prospective study is warranted to validate our findings.